KRN5
目录号 : GC31489KRN5是T细胞激活核因子(NFAT5)的抑制剂,其IC50值为750nM.
Cas No.:1800465-47-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
KRN5 is a Nuclear factor of activated T cells 5 (NFAT5) suppressor, with an IC50 of 750 nM.
The plasma half-life of KRN5 is estimated at >8 h when KRN5 is administered orally, and the bioavailability (F%) after oral and intravenous administration was 15% in rats. The IC50 value of KRN5 is 0.75 μM as determined by NFAT5-dependent reporter assay in LPS-stimulated RAW 264.7 cells, suggesting that the in vitro NFAT5 inhibitory capacity can be maintained after chemical modification of KRN2 to KRN5. Moreover, KRN5 is less toxic than BBR as determined by a cytotoxicity assay, hERG K+ channel assay, cytochrome inhibition assay, and liver microsomal metabolic stability test. KRN5 at a concentration of 1 μM inhibits the expressions of NFAT5, IL-6, MCP-1, and GM-CSF, which are NFAT5 target molecules, in RAW264.7 macrophages stimulated with LPS[1].
It is found that oral feeding of KRN5 every other day for 3 weeks from day 21 dose-dependently mitigates arthritis severity. When compared to methotrexate, a commonly used DMARD, the efficacy of oral KRN5 at 60mg/kg is more potent in suppressing arthritis; a supra-therapeutic dose (5 mg/kg) of methotrexate is administered orally twice a week for the same experimental period. Of special interest, no side effects are noted throughout the course of our experiments. The concentration of serum anti-type II collagen IgG also significantly decrease in the sera of KRN5-treated mice. In parallel, TNF-α and IL-6 production by LPS-stimulated splenocytes are significantly lower in KRN5-treated CIA mice than in vehicle-treatedmice. NFAT5 expression in spleen cells stimulated by LPS is also reduced by KRN5[1].
[1]. Han EJ, et al. Suppression of NFAT5-mediated Inflammation and Chronic Arthritis by Novel κB-binding Inhibitors. EBioMedicine. 2017 Apr;18:261-273.
Cas No. | 1800465-47-7 | SDF | |
Canonical SMILES | COC1=C(OC)C2=C(C=C1)C(CC3=CC=CC=C3F)=C4N(C2=O)CCC(C4=C5)=CC6=C5OCO6 | ||
分子式 | C27H22FNO5 | 分子量 | 459.47 |
溶解度 | DMSO : 6 mg/mL (13.06 mM);Water : < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.1764 mL | 10.8821 mL | 21.7642 mL |
5 mM | 0.4353 mL | 2.1764 mL | 4.3528 mL |
10 mM | 0.2176 mL | 1.0882 mL | 2.1764 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。